Target intelligence / Profile preview

Chromatin architecture (3D genome)

Target
3D genome
Molecular classification
Other, Epigenetic regulator, DNA-protein complex
01

Overview

Chromatin architecture refers to the complex three-dimensional organization of the genome within the nucleus, which is essential for coordinating gene expression by facilitating spatial interactions between distal regulatory elements like enhancers and their target promoters (Nature Reviews Genetics, 2020). This organization is hierarchical, consisting of chromatin loops, Topologically Associating Domains (TADs), and large-scale A/B compartments that define active and inactive genomic regions. In various diseases, particularly cancer, these structures are frequently disrupted through mutations in architectural proteins like CTCF or cohesin, or through the creation of 'neo-loops' that drive oncogene expression via enhancer hijacking (Science, 2016). Therapeutic strategies targeting chromatin architecture involve small molecules and PROTACs that modulate epigenetic readers, writers, and erasers to restore healthy genomic conformations or disrupt pathological interactions (Nature, 2018). As a high-level regulatory target, the 3D genome offers a sophisticated approach to precision medicine by addressing the structural basis of dysregulated gene expression patterns (Cell, 2019).

Other names
3D genome organizationHigher-order chromatin structureTopologically Associating Domains (TADs)Chromatin loopsNuclear architectureSpatial genome organization
02

Mechanism of action

Modulation of enhancer-promoter interactions and restoration of chromatin boundaries through the inhibition or degradation of architectural and epigenetic proteins such as BET bromodomains, HDACs, and EZH2.

03

Biological functions

Gene regulationDNA replicationDNA repairTranscription controlCell differentiation
04

Disease associations

CancerNeurodegenerative diseaseDevelopmental disorderAutoimmune diseaseCardiovascular disease
05

Safety considerations

Global transcriptional dysregulationPotential for genomic instabilityPleiotropic effects across multiple tissuesDevelopmental toxicityOff-target gene silencing or activation
06

Interacting drugs

JQ1

5 more in the full profile.

07

Biomarkers

CTCF binding profilesH3K27ac enrichment (Super-enhancers)Hi-C contact mapsTAD boundary integrity scoresChIA-PET interaction frequency

Beyond the preview

Go deeper on Chromatin architecture (3D genome).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromatin architecture (3D genome).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call